Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.

J Virol. 2000 Jul;74(13):6207-12. Unique Identifier : AIDSLINE MED/20305019
Gradoville L; Gerlach J; Grogan E; Shedd D; Nikiforow S; Metroka C; Miller G; Department of Pediatrics, Yale University School of Medicine, New; Haven, CT 06520, USA.

Abstract: Rta, the gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) encoded mainly in open reading frame 50 (ORF50), is capable of activating expression of viral lytic cycle genes. What was not demonstrated in previous studies was whether KSHV Rta was competent to initiate the entire viral lytic life cycle including lytic viral DNA replication, late-gene expression with appropriate kinetics, and virus release. In HH-B2, a newly established primary effusion lymphoma (PEL) cell line, KSHV ORF50 behaved as an immediate-early gene and autostimulated its own expression. Expression of late genes, ORF65, and K8.1 induced by KSHV Rta was eliminated by phosphonoacetic acid, an inhibitor of viral DNA polymerase. Transfection of KSHV Rta increased the production of encapsidated DNase-resistant viral DNA from HH-B2 cells. Thus, introduction of an ORF50 expression plasmid is sufficient to drive the lytic cycle to completion in cultured PEL cells.

Keywords: JOURNAL ARTICLE Deoxyribonucleases DNA, Viral/METABOLISM *Gene Expression Regulation, Viral/DRUG EFFECTS Herpesvirus, Kaposi Sarcoma-Associated/*GENETICS Human Immediate-Early Proteins/GENETICS/*METABOLISM Lymphoma Phosphonoacetic Acid/PHARMACOLOGY Reverse Transcriptase Inhibitors/PHARMACOLOGY RNA, Messenger Support, U.S. Gov't, P.H.S. Trans-Activators/GENETICS/*METABOLISM Tumor Cells, Cultured
001030
A00A0714

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .